Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

Inclusion Criteria: * Written informed consent. * Age\>18 years old. * Negative serum pregnancy test (in women of childbearing only). * Patients submitted to endovascular procedures below-the-knee by not exclusively. * Patient understands and is willing and able to comply with the study instructions and follow-up visit. * More than 70% stenosis or occlusion of the three distal arteries including or not the tibiofibular trunk (TFT). * Tissue loss (Rutherford 5). * One or more patent vessel of pedal arch. Exclusion Criteria: * TASC II D femoral and/or popliteal occlusion. * Life expectancy less than 1 year. * Allergy or contraindication to apixaban treatment. * Allergy or contraindication to dual antiplatelet treatment. * Creatinine clearance less than 30mL/min. * Planned major amputation before procedure. * Hybrid procedure (open and endovascular). * Use of fibrinolytic in the past 10 days. * Known HIV infection. * Liver disease (acute or chronic hepatitis and cirrhosis). * Drug addiction or alcohol abuse 12 months before the randomization. * Concomitant medications thatinhibit the CYP 3A4 cytochrome and P glycoprotein (ketoconazole, Iitraconazole, ritonavir). * Platelets count inferior to 100x109/L. * INR more than 1.5. * History or condition with high risk of bleeding: Eg. Trauma within 30 days before randomization, gastrointestinal bleeding 6 month before the randomization, intra-ocular, spinal, intra-articular bleeding (any time before), AV malformation, cerebral aneurysm and hypertension without control.